A detailed history of Dimensional Fund Advisors LP transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 36,141 shares of ENOB stock, worth $166,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,141
Previous 36,149 0.02%
Holding current value
$166,248
Previous $166,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
N/A
-8 Reduced 0.02%
36,141 $166,000
Q4 2023

Feb 07, 2024

BUY
$4.3 - $4.7 $64,267 - $70,246
14,946 Added 70.49%
36,149 $166,000
Q3 2023

Nov 09, 2023

BUY
$0.0 - $4.46 $0 - $37,771
8,469 Added 66.51%
21,203 $94,000
Q2 2023

Aug 09, 2023

SELL
$0.4 - $1.3 $3 - $10
-8 Reduced 0.06%
12,734 $7,000
Q1 2023

May 12, 2023

SELL
$0.91 - $1.31 $10 - $15
-12 Reduced 0.09%
12,742 $11,000
Q4 2022

Feb 09, 2023

SELL
$1.03 - $2.13 $7,918 - $16,375
-7,688 Reduced 37.61%
12,754 $13,000
Q3 2022

Nov 10, 2022

SELL
$1.7 - $2.86 $63,075 - $106,114
-37,103 Reduced 64.48%
20,442 $37,000
Q2 2022

Aug 12, 2022

SELL
$1.93 - $8.73 $17,149 - $77,574
-8,886 Reduced 13.38%
57,545 $111,000
Q1 2022

May 13, 2022

SELL
$4.42 - $9.0 $62,958 - $128,196
-14,244 Reduced 17.66%
66,431 $548,000
Q3 2021

Nov 12, 2021

SELL
$4.56 - $7.88 $683 - $1,182
-150 Reduced 0.19%
80,675 $543,000
Q2 2021

Aug 12, 2021

SELL
$2.94 - $6.79 $12,042 - $27,811
-4,096 Reduced 4.82%
80,825 $402,000
Q1 2021

May 14, 2021

BUY
$3.02 - $4.51 $62,731 - $93,681
20,772 Added 32.38%
84,921 $301,000
Q4 2020

Feb 25, 2021

BUY
$2.82 - $3.55 $180,900 - $227,728
64,149 New
64,149 $189,000

Others Institutions Holding ENOB

About Enochian Biosciences Inc


  • Ticker ENOB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,950,000
  • Market Cap $244M
  • Description
  • Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...
More about ENOB
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.